The world's largest private pharmaceutical group ---- Germany Bollinger Yinghan changed the conservative image of merging acquisitions in the past，It is announced that it will expand the Chinese market through mergers and acquisitions in the next 3 to 5 years。
    Yesterday，Bollinger China CEO Pan Dawei revealed，While continuously listed new products to expand the prescription drug business，Bollinger will strengthen its OTC business in China by merging Chinese pharmaceutical companies，and are ready to enter the field of Chinese medicine in China。
    Bollinger, who entered the OTC market in China in 2006, currently has only a brand of "Mu My stake betting appMy stake betting appShutan" in this field，and because of its high price，The current market is mainly concentrated in large and medium cities。
    "The new medical reform has opened the Chinese and medium -sized cities and rural markets，This will also be the focus of the company's next expansion。"Pan Dawei revealed，The company is currently negotiating mergers and acquisitions with 2-3 companies in China，The direction of mergers and acquisitions will focus on low prices、Regional -covered pharmaceutical companies。
    multinational pharmaceutical companies generally face 2%bottlenecks in the Chinese market，That is to say, the share of a single enterprise sales in the Chinese pharmaceutical market is difficult to exceed 2%。This，Pan Dawei stake betting appthinks，The only way to break stake sports betting appthrough the 2%bottleneck is to expand the business area。
    Bollinger's global sales last year were 12.7 billion euros，The first of the multinational pharmaceutical companies，Prescription drugs are currently the largest business unit of Bollinger，80%of its sales。